ALZN (Alzamend Neuro) ROC (Joel Greenblatt) %: -3,489.36% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALZN Alzamend Neuro Inc ALZN
21 GF Score
Price $1.33
! 1 Warning Sign
View Full Analysis

What is Alzamend Neuro ROC (Joel Greenblatt) %?

Alzamend Neuro ALZN +0.75% 21 ROC (Joel Greenblatt) % is -3,489.36% as of Apr. 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,320 Biotechnology companies, Alzamend Neuro ranks worse than 76.97% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Alzamend Neuro's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -3,489.36%.

The historical rank and industry rank for Alzamend Neuro's ROC (Joel Greenblatt) % or its related term are showing as below:

ALZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16251.37   Med: -2365.99   Max: -819.7
Current: -2366.63

During the past 8 years, Alzamend Neuro's highest ROC (Joel Greenblatt) % was -819.70%. The lowest was -16251.37%. And the median was -2365.99%.

ALZN's ROC (Joel Greenblatt) % is ranked worse than
76.97% of 1320 companies
in the Biotechnology industry
Industry Median: -297.06 vs ALZN: -2366.63

Alzamend Neuro's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.50% per year.


Alzamend Neuro  (NAS:ALZN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Alzamend Neuro ROC (Joel Greenblatt) % Related Terms


Alzamend Neuro ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Alzamend Neuro's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro ROC (Joel Greenblatt) % Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -4,867.98 -16,251.37 -7,764.06 -1,494.02 -2,365.99

Alzamend Neuro Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,393.27 -2,621.36 -1,039.58 -2,466.20 -3,489.36

ALZN vs SILO, BGMS, ENVB: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Alzamend Neuro's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzamend Neuro ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's ROC (Joel Greenblatt) % falls into.


ALZN
21GF Score
Alzamend Neuro Inc ALZN
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzamend Neuro ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.986) - (1.857 + 0 + 0)
=-0.871

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.053) - (1.346 + 0 + 0)
=-0.293

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Alzamend Neuro for the quarter that ended in Apr. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.48/( ( (0.343 + max(-0.871, 0)) + (0.315 + max(-0.293, 0)) )/ 2 )
=-11.48/( ( 0.343 + 0.315 )/ 2 )
=-11.48/0.329
=-3,489.36 %

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -3,489.36% mean?
Alzamend Neuro (ALZN) has a ROC (Joel Greenblatt) % of -3,489.36% as of Apr. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Alzamend Neuro and its competitors. According to the industry distribution chart, Alzamend Neuro ranks #1016 out of 1320 companies in the Biotechnology industry, placing it in the top 77%.
Is Alzamend Neuro's ROC (Joel Greenblatt) % too high?
Alzamend Neuro's current ROC (Joel Greenblatt) % is -3,489.36%. Based on the distribution chart, Alzamend Neuro ranks #1016 out of 1320 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's ROC (Joel Greenblatt) % compare to SILO and BGMS?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #1016 out of 1320 companies for ROC (Joel Greenblatt) %. This places Alzamend Neuro in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Alzamend Neuro and its competitors. Alzamend Neuro's current ROC (Joel Greenblatt) % is -3,489.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current ROC (Joel Greenblatt) % of -3,489.36%. The current ROC (Joel Greenblatt) % is -3,489.36%. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current ROC (Joel Greenblatt) % is -3,489.36% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzamend Neuro Business Description

Address 3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score

Get the complete analysis for ALZN

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price